Ariceum Therapeutics doses first patient with its first-in-class targeted radiopharmaceutical drug satoreotide in its Phase Ib study in small cell lung cancer

/PRNewswire/ -- Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain...

Related Keywords

Berlin ,Germany ,Australia ,United Kingdom ,United States ,Switzerland ,Austria ,Vienna ,Wien ,Perth ,Western Australia ,America ,Australian ,Germo Gericke ,Pureos Bioventures ,Marie Curie ,Oncology Theranostics Committee ,Life Sciences ,Murdoch University Health Center ,European Association Of Nuclear Medicine Congress ,European Association ,Nuclear Medicine Congress ,Satoreotide Trizoxetan ,Australian Clinical Trials ,Chief Executive Officer ,Ariceum Therapeutics ,Chief Medical Officer ,Rated Oral Presentations ,Andera Partners ,Earlybird Venture ,